Divi's Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Divi's Laboratories reported strong FY25 results with standalone revenue from operations growing 20% to ₹9,198 crore (vs ₹7,665 crore in FY24) and consolidated revenue at ₹9,360 crore (up ~19%). Standalone profit after tax jumped ~40% to ₹2,209 crore from ₹1,576 crore, while consolidated PAT rose ~37% to ₹2,191 crore. Standalone EPS for the year stood at ₹83.20 versus ₹59.37 last year. The board recommended a final dividend of ₹30 per share (1500%) on the ₹2 face value, subject to shareholder approval, with record date July 25, 2025. The Unit III greenfield project at Kakinada, Andhra Pradesh commenced commercial operations during the quarter. Price Waterhouse issued an unmodified audit opinion on both standalone and consolidated results, and the company adopted the lower Section 115BAA tax regime from FY25.
Strong double-digit revenue and profit growth, healthy dividend payout, new manufacturing capacity going live, and clean audit opinion are positives for shareholders. The CFO transition (L. Kishore Babu retiring, Venkatesa Perumallu Pasumarthy taking over from August 1, 2025) is a routine succession and likely to be neutral for the stock.